Last Updated on November 27, 2022 by The Health Master
The company now plans to de-prioritize the development of the drug, called poziotinib, and said it was in the process of cutting 75 percent of its research and development workforce.
Spectrum had 164 employees as of Dec 31, 2021.
The health regulator’s decision is in line with an advisory panel’s recommendation to not approve the drug.
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon: